RT Journal Article
SR Electronic
T1 Enhancing the brain’s emotion regulation capacity with a randomised trial of a 5-week heart rate variability biofeedback intervention
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.28.21264206
DO 10.1101/2021.09.28.21264206
A1 Nashiro, Kaoru
A1 Min, Jungwon
A1 Yoo, Hyun Joo
A1 Cho, Christine
A1 Bachman, Shelby L.
A1 Dutt, Shubir
A1 Thayer, Julian F.
A1 Lehrer, Paul
A1 Feng, Tiantian
A1 Mercer, Noah
A1 Nasseri, Padideh
A1 Wang, Diana
A1 Chang, Catie
A1 Marmarelis, Vasilis Z.
A1 Narayanan, Shri
A1 Nation, Daniel A.
A1 Mather, Mara
YR 2021
UL http://medrxiv.org/content/early/2021/09/30/2021.09.28.21264206.abstract
AB Heart rate variability is a robust biomarker of emotional well-being, consistent with the shared brain networks regulating emotion regulation and heart rate. While high heart rate oscillatory activity clearly indicates healthy regulatory brain systems, can increasing this oscillatory activity also enhance brain function? To test this possibility, we randomly assigned 106 young adult participants to one of two 5-week interventions involving daily biofeedback that either increased heart rate oscillations (Osc+ condition) or had little effect on heart rate oscillations (Osc- condition) and examined effects on brain activity during rest and during regulating emotion. In this healthy cohort, the two conditions did not differentially affect anxiety, depression or mood. However, the Osc+ intervention increased low-frequency heart rate variability and increased brain oscillatory dynamics and functional connectivity in emotion-related resting-state networks. It also increased down-regulation of activity in somatosensory brain regions during an emotion regulation task. The Osc- intervention did not have these effects. These findings indicate that heart rate oscillatory activity not only reflects the current state of regulatory brain systems but also changes how the brain operates beyond the moments of high oscillatory activity.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03458910Funding StatementThis study was supported by NIH R01AG057184 (PI Mather).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Southern California (USC) Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData supporting the findings of this study will be made publicly available at OpenNeuro.